division commercializes Finished Dosage Forms
in highly regulated markets such as North America,
EU and Australia.
Global Generics Product details
RPG Life Sciences established its operations
in the regulated market back in 2004 and
in a short span of 7 years it has achieved significant
growth in the European market in the chosen areas
of therapeutic categories. Global Generics division
provides strengths in the Immunosuppressant
therapy to the company.
Azathioprine is a flagship product for RPG Life
Sciences which has dominant markets share worldwide
in the Immunosuppressant therapy. Company plans
to expand its footprint in the same therapy
with complex molecules to represent it in
all the dosage forms.
Outstanding service levels can be attributed
to the dedicated customer service teams put
in place to ensure smooth transition of products
from the manufacturing locations in India to
the farthest regions of Canada and European
territories. RPGLS' long business relationships with major Generic companies in the world are testimonies of its strong customer focus.